Developing an AI-powered bedside device for multimodal imaging for microcirculation monitoring and early sepsis diagnosis.
Sepsiscan
Riga (LV) · Liverpool (GB) · Mannheim (DE)New on Amplifa
About Sepsiscan
Sepsiscan is a medical technology company and university spinoff founded in 2023 with an exclusive IP license. It develops a software-controlled, AI-based bedside device for multimodal imaging (hyperspectral and thermography imaging) that assesses blood microcirculation non-invasively, in real time and at the patient's bedside. The system maps the temperature distribution, visually displays blood oxygen deficiency and detects early sepsis signs such as mottling, supporting intensive care units in managing sepsis treatment. Based on university research, two prototypes have been tested on more than 100 patients; initial international patient demonstrations took place at Hôpital Bicêtre (France). Reference letters have been provided, among others, by Riga East Clinical University Hospital, Riga Stradins University and the Latvian Association of Anaesthesiology and Reanimatology. Locations are in Riga (Latvia), Liverpool (United Kingdom, international headquarters since 2026) and Mannheim (Germany).
- Site
- LV-1046 Rīga
- Processes
- Non-invasive assessment of blood microcirculation, Temperature distribution mapping, Real-time measurement and instant results, Hyperspectral and thermography imaging with AI software for early sepsis detection
- Materials
- Hyperspectral imaging, Thermography imaging, AI software
- Founded
- 2023
- Employees
- 5
- Industries
- Medical technology, Medical diagnostics, Intensive care (ICU), Sepsis diagnostics
- 01
University research and prototype development
- 02
Hyperspectral and thermography imaging
- 03
AI software analysis (Microsoft Azure AI, NVIDIA Inception)
- 04
Clinical validation on patients
- 05
Support of intensive care units
Technology & Processes
Hyperspectral imaging
Acquisition of multiple images in narrow, non-overlapping spectral bands for spatial representation of skin oxygen saturation.
Thermography imaging
Mapping of the temperature distribution for non-invasive assessment of microcirculation.
AI software
Software-based detection of blood oxygen deficiency and early sepsis signs in real time.
Locations
Riga (Āgenskalna iela 33, LV-1046)
LVSite
Riga (Slokas iela 120a, LV-1067)
LVHeadquarters
Liverpool (Central Tech, 31 Russell Street, L3 5LJ)
GBInternational headquarters (since 2026)
Mannheim (Cubex One, Franz-Volhard-Straße 5, 68167)
DESite (Cubex One)
Products & Components
Inside the production
Industries
Additional services
Reference customers
History
- 2016-2022
University research, 2 prototypes tested on 100+ patients, EUR 1 million invested
- 2022
Completed Buildit Accelerator Batch15, idea validated
- 2023-02
Exclusive IP license received, spinoff founded
- 2023-05
Health Founders Accelerator Batch IV
- 2024-01
Convertible note of EUR 50,000 from Commercialization Reactor (Latvia)
- 2024-07
EUR 60,000 R&D cascade funding grant received
- 2024-07
First international demonstration on real patients (Hôpital Bicêtre, France)
- 2024-07
Startupbootcamp DeepTech & Robotics Class 2024
- 2024-08
EIT Health Innostars Awards Finalist (Validation Track)
- 2024-09
Life Sciences Acceleration LSA program (Mannheim, Germany)
- 2024-10
Microsoft for Startups Founders Hub (Azure AI)
- 2025-07
Medical Innovations Incubator 4C program (Tübingen, Germany) completed
- 2025-10
EUR 52,500 grant from the Latvian Investment and Development Agency
- 2026-01
International headquarters (new company) registered in the United Kingdom
- 2026-02
Admitted to the NVIDIA Inception program
- 2026
Seal of Excellence of the European Commission (EIC preAccelerator Call)